Completed PHASE1 INTERVENTIONAL 3-arm NCT00023647

Vaccine Therapy in Treating Patients With Stage IV Melanoma

A Phase I Dose-Ranging Safety Study Using Intranodal Delivery of a Plasmid DNA (Synchrotope TA2M) in Adult Stage IV Melanoma Patients

Sponsor: Mannkind Corporation

Conditions Melanoma (Skin)

Interventions Synchrotope TA2M

Updated 6 times since 2017 Last updated: Jul 9, 2012 Started: Jul 31, 2000 Primary completion: Apr 30, 2002 Completion: Nov 30, 2002

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Melanoma (Skin), this trial is completed. The trial is conducted by Mannkind Corporation and has accumulated 6 data snapshots since 2000. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Jul 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Mannkind Corporation

Data source: Mannkind Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Los Angeles, United States